Metagenomi/$MGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Metagenomi
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
Ticker
$MGX
Sector
Health
Primary listing
Employees
176
Headquarters
Website
Metagenomi Metrics
BasicAdvanced
$72M
-
-$2.11
-
-
Price and volume
Market cap
$72M
52-week high
$4.40
52-week low
$1.23
Average daily volume
881K
Financial strength
Current ratio
5.846
Quick ratio
5.73
Long term debt to equity
18.261
Total debt to equity
20.896
Profitability
EBITDA (TTM)
-82.197
Gross margin (TTM)
-127.30%
Net profit margin (TTM)
-172.21%
Operating margin (TTM)
-193.73%
Effective tax rate (TTM)
6.50%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
-15.37%
Return on equity (TTM)
-31.93%
Valuation
Price to revenue (TTM)
1.569
Price to book
0.34
Price to tangible book (TTM)
0.34
Price to free cash flow (TTM)
-0.679
Free cash flow yield (TTM)
-147.18%
Free cash flow per share (TTM)
-2.826
Growth
Revenue change (TTM)
-4.22%
Earnings per share change (TTM)
-78.63%
What the Analysts think about Metagenomi
Analyst ratings (Buy, Hold, Sell) for Metagenomi stock.
Metagenomi Financial Performance
Revenues and expenses
Metagenomi Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Metagenomi stock?
Metagenomi (MGX) has a market cap of $72M as of August 12, 2025.
What is the P/E ratio for Metagenomi stock?
The price to earnings (P/E) ratio for Metagenomi (MGX) stock is 0 as of August 12, 2025.
Does Metagenomi stock pay dividends?
No, Metagenomi (MGX) stock does not pay dividends to its shareholders as of August 12, 2025.
When is the next Metagenomi dividend payment date?
Metagenomi (MGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Metagenomi?
Metagenomi (MGX) does not currently have a Beta indicator.